DDInter1407 DDInter624
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Peginterferon alfa-2a {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Zafirlukast {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Efavirenz
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Didanosine
Didanosine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Efavirenz
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Bedaquiline {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Peginterferon alfa-2a {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cyclophosphamide
Cyclophosphamide {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anagrelide
Anagrelide {u} (Compound) downregulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zafirlukast
Zafirlukast {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Cytochrome P450 2C9 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Efavirenz
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) upregulates {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Auranofin
Auranofin {u} (Compound) binds {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Peginterferon alfa-2a {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} (Compound) upregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Efavirenz (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didanosine (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Efavirenz (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide (Compound) downregulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Efavirenz (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) includes Efavirenz (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) upregulates IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Auranofin and Auranofin (Compound) binds IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) upregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Efavirenz (Compound)